Cargando…

The selective PGI(2) receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats

Pulmonary arterial hypertension (PAH) is a lethal disease characterized by a progressive increase in pulmonary artery pressure due to an increase in vessel tone and occlusion of vessels. The endogenous vasodilator prostacyclin and its analogs are used as therapeutic agents for PAH. However, their ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Honda, Yohei, Kosugi, Keiji, Fuchikami, Chiaki, Kuramoto, Kazuya, Numakura, Yuki, Kuwano, Keiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561119/ https://www.ncbi.nlm.nih.gov/pubmed/33057388 http://dx.doi.org/10.1371/journal.pone.0240692

Ejemplares similares

Antiproliferative effect of selexipag active metabolite MRE‐269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension
por: Kuramoto, Kazuya, et al.
Publicado: (2023)

Response to: Are endothelial cell proliferation and mesenchymal transition as distinguishing characteristics of 3-week Sugen5416/hypoxia mice model?
por: Rodor, Julie, et al.
Publicado: (2023)

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
por: Morales-Cano, Daniel, et al.
Publicado: (2023)

Sugen, hypoxia and the lung circulation
por: Voelkel, Norbert F., et al.
Publicado: (2021)

Shunt-type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron-based phase-contrast micro-CT
por: van der Have, Oscar, et al.
Publicado: (2022)

Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
por: Morales-Cano, Daniel, et al.
Publicado: (2023)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Transpulmonary amino acid metabolism in the sugen hypoxia model of pulmonary hypertension
por: Philip, Nicolas, et al.
Publicado: (2023)

Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition
por: Yu, Min, et al.
Publicado: (2020)

Intratracheal Administration of Prostacyclin Analogue–incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension
por: Akagi, Satoshi, et al.
Publicado: (2016)

Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats
por: Tornling, Göran, et al.
Publicado: (2023)

Increased Eicosanoid Levels in the Sugen/Chronic Hypoxia Model of Severe Pulmonary Hypertension
por: Al-Husseini, Aysar, et al.
Publicado: (2015)

Spatial and temporal resolution of metabolic dysregulation in the Sugen hypoxia model of pulmonary hypertension
por: Simpson, Catherine E., et al.
Publicado: (2023)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells
por: Liu, Ping, et al.
Publicado: (2021)

Sugen–morphine model of pulmonary arterial hypertension
por: Agarwal, Stuti, et al.
Publicado: (2020)

Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Bogaard, Harm J., et al.
Publicado: (2019)

IL‐33/ST2 receptor‐dependent signaling in the development of pulmonary hypertension in Sugen/hypoxia mice
por: Indralingam, Cynthia S., et al.
Publicado: (2022)

SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model
por: Peloquin, Grace L., et al.
Publicado: (2019)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

MicroRNA-212-5p, an anti-proliferative miRNA, attenuates hypoxia and sugen/hypoxia-induced pulmonary hypertension in rodents
por: Chen, Tianji, et al.
Publicado: (2022)

Direct Delivery of MicroRNA96 to the Lungs Reduces Progression of Sugen/Hypoxia-Induced Pulmonary Hypertension in the Rat
por: Docherty, Craig K., et al.
Publicado: (2020)

Using extracellular matrix derived from sugen-chronic hypoxia lung tissue to study pulmonary arterial hypertension
por: Link, Patrick A., et al.
Publicado: (2023)

Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
por: Sanada, Takayuki J., et al.
Publicado: (2020)

Human Mesenchymal Stem Cell Therapy Reverses Su5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
por: Alencar, Allan K. N., et al.
Publicado: (2018)

The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats
por: Shoji, Hiroki, et al.
Publicado: (2021)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Natural reversal of pulmonary vascular remodeling and right ventricular remodeling in SU5416/hypoxia-treated Sprague-Dawley rats
por: Zungu-Edmondson, Makhosazane, et al.
Publicado: (2017)

Partially hydrolyzed guar gum suppresses the progression of pulmonary arterial hypertension in a SU5416/hypoxia rat model
por: Sanada, Takayuki J., et al.
Publicado: (2023)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
por: Hoch, Matthias, et al.
Publicado: (2014)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Isolated heart model demonstrates evidence of contractile and diastolic dysfunction in right ventricles from rats with sugen/hypoxia‐induced pulmonary hypertension
por: Neto‐Neves, Evandro M., et al.
Publicado: (2017)

Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2019)

Understanding longitudinal biventricular structural and functional changes in a pulmonary hypertension Sugen–hypoxia rat model by cardiac magnetic resonance imaging
por: Jayasekera, Geeshath, et al.
Publicado: (2020)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Wet Lab–Based Cataract Surgery Training Curriculum for the PGY 2/PGY 3 Ophthalmology Resident
por: Pantanelli, Seth M., et al.
Publicado: (2018)

SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling
por: Sitapara, Ravikumar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2o36u97p02dhd4o0v88f8fqvuh